Department of Chemistry, Maharishi Markandeshwar (Deemed to be University), Mullana-133207, Ambala, Haryana, India.
School of Pharmacy and Technology Management, SVKM's NMIMS, Hyderabad, Telangana-509301, India.
Anticancer Agents Med Chem. 2021;21(11):1379-1402. doi: 10.2174/1871520620666200728133017.
Cancer is second leading disease after cardiovascular disease. Presently, Chemotherapy, Radiotherapy and use of chemicals are some treatments available these days. Thiazole and its hybrid compounds extensively used scaffolds in drug designing and development of novel anticancer agents due to their wide pharmacological profiles. Fused thiazole scaffold containing drugs are available in market as a promising group of anticancer agents.
The detailed study has been done using different database that focused on potent thiazole hybrid compounds with anticancer activity. The literature included in this review is focused on novel fused thiazole derivatives exhibiting anticancer potency in last decade.
Literature suggested that thiazoles and its fused and linked congener serve excellent pharmacological profile as an anticancer agent. Various synthetic strategies for fused thiazole are also summarized in this article. Novel thiazole and its fused congener showed anticancer activity against various cancer cell lines.
Thiazole is a promising scaffold reported in literature with broad range of biological activities. This article covers the thiazole compounds fused with other carbocyclic/heterocycle including benzene, imidazole, pyridine, pyrimidine, quinoline, phenothiazine, thiopyrano, steroids, pyrrole etc. with anticancer activity from last decades. Several inhibitors for breast cancer, colon cancer, melanoma cancer, ovarian cancer, tubulin cancer etc. were reported in this review. Thus, this review will definitely aid to develop a lead for the new selective anticancer agents in future.
癌症是仅次于心血管疾病的第二大疾病。目前，化疗、放疗和化学物质的使用是当今可用的一些治疗方法。噻唑及其杂环化合物由于其广泛的药理学特性，广泛应用于药物设计和新型抗癌药物的开发中。含有噻唑骨架的融合药物已在市场上作为一种有前途的抗癌药物。
本研究使用不同的数据库对具有抗癌活性的强效噻唑杂合化合物进行了详细研究。本文综述的文献重点介绍了过去十年中具有抗癌活性的新型融合噻唑衍生物。
文献表明，噻唑及其融合和连接同系物作为抗癌剂具有出色的药理学特性。本文还总结了各种融合噻唑的合成策略。新型噻唑及其融合同系物对各种癌细胞系表现出抗癌活性。
噻唑是文献中报道的一种很有前途的支架，具有广泛的生物活性。本文综述了过去几十年中具有抗癌活性的与其他碳环/杂环（包括苯、咪唑、吡啶、嘧啶、喹啉、吩噻嗪、噻喃、甾体、吡咯等）融合的噻唑化合物。本文报道了几种针对乳腺癌、结肠癌、黑色素瘤、卵巢癌、微管癌等的抑制剂。因此，本综述将有助于未来开发新的选择性抗癌药物。
